Cell & Gene
Cell & Gene Therapies: An Overview Of FDA Regulatory Considerations For 2024
April 17, 2024
In an explicit effort to bring approved cell and gene therapies (CGT) to patients sooner, FDA has launched a number of initiatives and programs to address the pace of CGT approvals. In this article for Cell & Gene, Sidley’s Emily Marden and Kelly Cho share their insights on key regulatory developments relevant to sponsors seeking regulatory approval of CGTs for commercialization in the U.S.
View article here.
Contacts
Capabilities
Suggested News & Insights
U.S. Drug Pricing Year in Review: Reflections on 2025 and Getting Ready for 2026December 12, 2025BIOSECURE Act Included in the FY2026 National Defense Authorization ActDecember 12, 2025Sidley Ranked in Chambers Asia-Pacific 2026December 11, 2025U.S. Drug Pricing Year in Review: Reflections on 2025 and Getting Ready for 2026December 11, 2025What the U.S.–UK Drug Pricing Agreement Reveals About How MFN Drug Policy Could Impact the UK and EUDecember 10, 2025What the U.S.–UK Drug Pricing Agreement Reveals About How MFN Drug Policy Could Impact the UK and EUDecember 10, 2025
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory